メインコンテンツにスキップ

Certara Awarded European Medicines Agency Project to Assess Real-World Data Landscape for CAR-T Cell Therapies

Project will evaluate content, quality, and accessiblity of available real-world data sources for six CAR-T cell therapies currently approved for use in the European Union (EU) Radnor, PA – 2025年1月22日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in model-informed drug development, announced the award of a European Medicines Agency (EMA) project to … Continued

Certara Appoints New Head of Biometrics, Data Science, and Access

RADNOR, PA. – 2025年1月10日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in model-informed drug development, today announced the appointment of Tiffany Woodworth as Head of Biometrics, Data Science and Access. This strategic appointment underlines Certara’s commitment to advancing its capabilities in modeling and simulation, regulatory science, and market access. In this role, … Continued

Certara Launches Updated Version of SEND Explorer® Software

Expanded visualizations and data standards support workflows for preclinical scientists and toxicologists Radnor, PA – 2024年12月18日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in model-informed drug development, announced the availability of version 12.0 of the SEND Explorer® Product Family, released in November. SEND Explorer provides scientists advanced viewing, data summarization, and visualization capabilities for nonclinical study data using … Continued

Major Release of Certara GlobalSubmit™ Software Enhances the Regulatory Submission Process

Radnor, PA – 2024年11月25日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in model-informed drug development, today announced that a new version of its GlobalSubmit regulatory submissions software is generally available. The latest version supports the FDA’s new version 4.0 submission standard, improving the submission process while increasing harmonization across health authorities’ requirements. … Continued

Certara Establishes Certainty Conference in Europe, Creating Space for Drug Development Leaders to Convene

Clients are invited to join Certara at this two-day event to further explore and connect on the future of drug development   RADNOR, PA – OCTOBER 24, 2024 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in model-informed drug development, today announced that it is continuing to scale its premier client summit Certainty in Europe. Prior … Continued

Certara Releases Environmental, Social and Governance Report

Report details commitment to understanding, monitoring, and managing social and environmental responsibilities.  RADNOR, Pa. — 2024年10月23日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in model-informed drug development (MIDD), today announced that it has issued its 2024 environmental, social and governance (ESG) report. The report outlines Certara’s approach to a responsible ESG framework … Continued

Certara Drug Development & Regulatory Experts Achieve 100th Rare Disease Submission

Dedicated team of global regulatory experts drives the approval of rare disease treatments   RADNOR, Pa. — 2024年10月1日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in model-informed drug development (MIDD), today announced it has successfully supported 100 rare disease drug submissions to regulatory agencies worldwide. Submissions include Investigational New Drug (IND), initial Clinical … Continued

Certara Launches Early Development Solution to Reduce Failure Rates in Early-Stage Drug Development

New solution offers early-stage developers a dedicated team of experts with combined experience in end-to-end drug development to optimize delivery timelines, derisk programs, and improve outcomes. ペンシルベニア州ラドナー:2024年9月19日 - バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in model-informed drug development, today launched its Early Development Solution. The offering enhances early-stage development … Continued

サターラ、アジア太平洋地域の医薬品開発リーダー向けにCERTAINTYフォーラム開催

中国、韓国、日本にて開催されるサターラ主催フォーラムを通して、モデルを活かした医薬品開発(MIDD)アプローチを活用し新薬をより早く患者に届けることを目指す研究者の交流と情報交換を促進ペンシルベニア州ラドナー:2024年9月3日 - バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in model-informed drug development, today announced that it is expanding its premier client event, … Continued

Certara Research Reveals IRA’s Impact on Biosimilar Uptake

RADNOR, PA – 2024年8月15日 — Certara, Inc., a global leader in model-informed drug development, has published new research on the impact of the Inflation Reduction Act (IRA) on oncology biosimilar uptake. Signed into law two years ago, the IRA was intended to expand benefits and lower costs for Medicare beneficiaries. One way the … Continued

1 of 4
Powered by Translations.com GlobalLink Web Software